Abstract
With a prevalence rising with age from 0.05% at age 25-35 years to more than 5% among people aged 69 years or more, atrial fibrillation (AF) and in general atrial tachyarrhythmias (AT) are now the single most common sustained arrhythmia [1]. Once considered a benign disease, AF is increasingly being recognized as a significant cause of morbidity and mortality. AT can be treated by a vast array of pharmaceutical and nonpharmacological therapies, suggesting that no single treatment is sufficiently simple, successful, and cheap to exclude other therapies. Many new therapies are presently being developed, among which are electrical therapies designed to prevent and convert AT. Clinical experience indicates that monotherapeutic approaches (drug, ablation, or device) are often associated with unsatisfactory results in the treatment of AT patients [1-12]. Because all therapies have poor efficacy when considered alone, interest in the role of combinations of therapies (hybrid therapy) has recently increased. The rationale underlying hybrid therapy is that a combination of modalities of intervention in AT might have a synergistic effect, with the efficacy of each intervention building upon that of the others [12]. At present this concept is being considered particularly in the prevention of AT recurrence, but hybrid therapy has also been utilized both in facilitating restoration to sinus rhythm and in control of heart rate.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Narayan SM, Cain ME, Smith JM (1997) Atrial fibrillation. Lancet 350:943–950
Pritchett ELC, McCarthy EA, Wilkinson WE (1991) Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 114:539–544
Coplen SE, Antman AM, Berlin JA, Hewitt P, Chaimers TC (1990) Efficacy and safety of quinidine therapy for mantenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 82:1106–1116
Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG, on behalf of the Stroke Prevention in AF Investigators (1992) Antiarrhythmic drug therapy and cardiac mortality in AE J Am Coll Cardiol 20:527–532
Cox JL, Canavan TE, Schuessler RB et al (1991) The surgical treatment of AF. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and AF. J Thorac Cardiovasc Surg 101: 408–426
Jais P, Haïssaguerre M, Shah DC et al (1997) A focal source of AF treated by discrete radiofrequency ablation. Circulation 95:572–576
Haïssaguerre M, Jais P, Shah DC et al (1996) Right and left atrial radiofrequency catheter therapy of paroxysmal AF. J Cardiovasc Electrophysiol 12:1132–1144
Ching Man K, Daoud E, Knight B et al (1996) Right atrial radiofrequency catheter ablation of paroxysmal AF. J Am Coll Cardiol 27:188A (Abstract)
Rosenqvist M, Brandt J, Schuller H (1988) Long-term pacing in sinus node disease: effect of stimulation mode on cardiovascular mortality and morbidity. Am Heart J 116:16–22
Sgarbossa EB, Pinski SL, Maloney JD et al (1993) Chronic AF and stroke in paced patients with sick sinus syndrome. Relevance of clinical characteristics and pacing modalities. Circulation 88:1045–1053
Jung W, Wolpert C, Esmailzadeh B et al (1998) Specific considerations with the automatic implantable atrial defibrillator. J Cardiovasc Electrophysiol 9(8 Suppl):S193–201
Timmermans C, Levy S, Ayers GM et al (2000) Spontaneous episodes of atrial fibrillation after implantation of the Metrix Atrioverter: observations on treated and non-treated episodes. Metrix Investigators. J Am Coll Cardiol 35(6):1428–1433
Capucci A, Villani GQ (2000) Combined approach of pharmacological and non-pharmacological treatment of atrial fibrillation. In: Bloch-Thomsen PE, Clement DL.Everyday problems in cardiology. Excerpta Medica, Amsterdam, vol II, no 2, pp 3–8
Default P, Saksena S, Prakash A et al (1998) Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single-dual-site right atrial pacing for arrhythmia prevention. J Am Coll Cardiol 32:1900–1908
Saksena S, Prakash A, Michael H et al (1996) Prevention of recurrent AF with chronic dual-site right atrial pacing. J Am Coll Cardiol 28:687–694
Vardas PE et al (1998) Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic AE Am .J Cardiol 81: 995–998
Roy D, Talajic M, Dorian P et al (2000) Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342:913–920
Ricci R, Santini M, Puglisi A et al (1999) Intermittent or continuous overdrive atrial pacing significantly reduces paroxysmal atrial fibrillation recurrences in brady-tachy syndrome. Pacing Cling Electrophysiol 22:A175 (abstract)
Barold S et al (1987) Implanted atrial pacemakers for paroxysmal atrial flutter. Ann Intern Med 107:144–149
Connelly DT, de Belder MA, Cunningham D et al (1993) Long-term follow-up of patients treated with a software-based antitachycardia pacemaker. Br Heart J 69:250–254
den Dulk K, Brugada P, Smeets J et al, (1990) Long-term antitachycardia pacing experience for supraventricular tachycardia. Pacing Clin Electrophysiol 13:1020–1030
den Dulk K et al (1983) A versatile pacemaker system for termination of tachycardias. Am J Card 52(7):731–738
Fromer M, Gloor H, Kus T (1990) Clinical experience with the Intertach pulse generator in patients with recurrent supraventricular and ventricular tachycardia. Pacing Clin Electrophysiol 13:1955–1959
Kappenberger L, Valin H, Sowton E (1989) Multicenter long-term results of antitachycardia pacing for supraventricular tachycardias. Am J Cardiol 64:191–193
McComb JM, Jameson S, Bexton R (1990) Atrial antitachycardia pacing in patients with supraventricular tachycardia: clinical experience with the Intertach pacemaker. Pacing Clin Electrophysiol 13:1948–1954
Adler SW, Wolpert C, Warman EN et al (2001) Efficacy of pacing therapies for treating atrial tachyarrhythmias in patients with ventricular arrhythmias receiving a dual-chamber implantable cardioverter defibrillator. Circulation 104: 887–892
Friedman PA, Dijkman B, Warman EN et al (2001) Atrial therapies reduce atrial arrhythamias burden in defibrillator patients. Circulation 104:1023–1028
Disertori M, Padeletti L, Santini M et al (2001) Antitachycardia pacing therapies to terminate atrial tachycardia: the AT500 Italian Registry. Eur Heart J Suppl .3[Suppl. P]P16–P24
Tsuji H, Fujiki A, Tani M et al (1992) Quantitative relationship between atrial refractoriness and the dispersion of refractoriness in atrial vulnerability. Pacing Clin Electrophysiol 15:403–410
Gallagher MM, Camm AJ (1997) Classification of atrial fibrillation. Pacing Clin Electrophysiol 20:1603–1605
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Italia
About this paper
Cite this paper
Gulizia, M. et al. (2003). Treatment of Atrial Fibrillation in Patients Affected by Sick Sinus Syndrome: Role of Prevention and Antitachycardia Pacing Algorithms. Preliminary Results from PITAGORA Study. In: Gulizia, M. (eds) New Advances in Heart Failure and Atrial Fibrillation. Springer, Milano. https://doi.org/10.1007/978-88-470-2087-0_53
Download citation
DOI: https://doi.org/10.1007/978-88-470-2087-0_53
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2169-3
Online ISBN: 978-88-470-2087-0
eBook Packages: Springer Book Archive